First TNF antagonist monotherapy | First TNF antagonist plus one csDMARD | First TNF antagonist plus two or more csDMARDs | Total | P* | |||||
---|---|---|---|---|---|---|---|---|---|
n, % | 234 | 21 | 766 | 67 | 136 | 12 | 1.136 | 100 | |
Gender, female n, % | 175 | 75 | 557 | 73 | 99 | 73 | 831 | 73 | 0.8 |
Rheumatoid factor (RF)+ n, % | 183 | 78 | 619 | 81 | 104 | 77 | 906 | 80 | 0.4 |
ACPA + n, % * | 47/71 | 66 | 330/431 | 77 | 47/70 | 67 | 424/ 572 | 74 | 0.06 |
RF- and ACPA- n, % | 12 | 5 | 64 | 8 | 14 | 10 | 90 | 8 | 0.07 |
Erosions n, % | 195 | 83 | 622 | 81 | 100 | 74 | 917 | 81 | 0.05 |
Rheumatoid nodules n, % | 50 | 21 | 189 | 25 | 18 | 13 | 257 | 23 | 0.01 |
Joint arthroplasty n, % | 15 | 6 | 66 | 9 | 3 | 2 | 84 | 7 | 0.02 |
Number of comorbidities n, % | |||||||||
0 | 67 | 30 | 159 | 22 | 51 | 42 | 277 | 26 | 0.003 |
1 | 32 | 14 | 72 | 10 | 12 | 10 | 116 | 11 | |
≥2 | 124 | 56 | 481 | 68 | 57 | 48 | 662 | 63 | |
Anti-hepatitis B antibody+ n, % | 2/47 | 4 | 7/194 | 4 | 0/26 | 0 | 9/267 | 3 | 0.2 |
Anti-hepatitis C antibody+ n, % | 6/46 | 13 | 6/195 | 3 | 2/26 | 8 | 14/267 | 5 | 0.05 |
PPD skin reaction + (≥5 mm) n, % | 24 | 10 | 120 | 16 | 17 | 13 | 161/1.112 | 14 | 0.09 |
Secondary Sjögren’s syndrome n, % | 44 | 19 | 128 | 17 | 17 | 12 | 189 | 17 | 0.2 |
Interstitial lung disease n, % | 16 | 7 | 25 | 3 | 1 | 0.7 | 42 | 4 | 0.007 |
Recurrent infections n, % | 5 | 2 | 11 | 1 | 1 | 0.7 | 17 | 2 | 0.54 |
Past cancer n, % | 4 | 2 | 5 | 0.6 | 0 | 0 | 9 | 0.8 | 0.1 |
Mean ± SD | |||||||||
Age (years) mean ± SD | 55.9 | ±13.7 | 52.8 | ±13.4 | 50 .7 | ±11.1 | 53.2 | ±13.3 | 0.0001 |
Duration of disease (years) mean ± SD | 9.4 | ±8.0 | 9.0 | ±7.5 | 8.8 | ±7.3 | 9.1 | ±7.6 | 0.8 |
Number of comorbidities mean ± SD | 2.2 | ±2.3 | 2.7 | ±2.4 | 1.9 | ±2.3 | 2.5 | ±2.4 | 0.0001 |
Tender joint count (0–28) mean ± SD | 10.9 | ±6.4 | 10.3 | ±6.6 | 11.6 | ±6.9 | 10.6 | ±6.6 | 0.0003 |
Swollen joint count (0–28) mean ± SD | 9.0 | ±6.1 | 7.9 | ±5.5 | 8.5 | ±5.8 | 8.2 | ±5.7 | 0.02 |
Pain visual analogue scale (0–100) mean ± SD | 61.9 | ±19.3 | 63.5 | ±22.2 | 66.0 | ±20.8 | 63.4 | ±21.5 | 0.01 |
DAS28-ESR mean ± SD | 5.9 | ±1.0 | 5.7 | ±1.1 | 5.7 | ±1.0 | 5.8 | ±1.1 | 0.03 |
HAQ score (0–3) mean ± SD | 1.40 | ±0.58 | 1.44 | ±0.65 | 1.6 | ±0.59 | 1.46 | ±0.63 | 0.0003 |
ESR (mm) mean ± SD | 45.7 | ±24.7 | 42.1 | ±25.8 | 32.7 | ±21.5 | 41.8 | ±25.3 | 0.0001 |
C-reactive protein (mg/L) mean ± SD | 19.3 | ±21.4 | 15.7 | ±21.5 | 15.8 | ±19.4 | 16.5 | ±21.2 | 0.0001 |